Tools   Select Another Resource Report Type

http://www.biobancusa.com/

BioBancUSA is a leading biotechnology company specializing in white blood cell collection, processing, cryopreservation and storage service. BioBancUSA, a private company headquartered in Monterey, California, is the exclusive licensee of the original patent for the collection, processing and cryopreservation technology of white blood cells, giving you the assurance of both technical integrity and legal legitimacy that you can count on. BioBancUSA is dedicated to providing our clients with the highest quality immune cell preservation for their future medical use. We are committed to the most advanced technology, exceptional, personalized service and leading-edge innovation to benefit our customers, health care providers, shareholders and employees.

Proper citation: Biobanc USA (RRID:SCR_010622) Copy   

•   Source: SciCrunch Registry

http://www.rucdr.org/

RUCDR is a biobank and a service organization that maintains human blood, serum, saliva, tissue and the genetic products derived from those. Services include technical consultation and logistical support for biobanking. Researchers can order biomaterials and apply for phenotypic / genotypic data.

Proper citation: Rutgers Cell and DNA Repository (RRID:SCR_010624) Copy   

•   Source: SciCrunch Registry

http://www.ntnu.edu/hunt

International biobank storing whole blood and DNA from 200,000 individuals, serum and plasma samples from more than 100,000 individuals as well as urine, RNA tubes, cells, buffy coat and Na-heparin tubes for environmental analysis for as many as 50,000 individuals. All bio-specimens from the HUNT surveys are collected, processed and stored at the HUNT Biobank in Levanger. The National CONOR Biobank is located on the same site, where it serves as a central research repository for DNA samples from all the largest Norwegian health surveys. These make up the Cohorts of Norway (CONOR), which include samples from more than 200,000 individuals. * HUNT 1 was carried out in 1984-1986 to establish the health history of 75,000 people. * HUNT 2, carried out in 1995-1997, focused on the evolution of the health history of 74,000 people. This included blood sample collection from 65,000 people. The data that accompany biospecimens in the biobank are stored in secured computer systems that run complex database management and analysis software. * HUNT 3 was completed in June 2008. 93,210 people were invited to participate in the study, and as of the 6th of June, 2008, 48,289 people participated (52% participation rate). The data, collected by means of questionnaires, interviews, clinical examinations and collection of blood and urine samples, will be ready for analysis in January 2009. * Young-HUNT is the adolescent part of HUNT including participants aged 13-19 years. Young-HUNT1 (1995-97) was conducted as part of HUNT2, 9141 adolescents participated (90% response rate). Young-HUNT2 (2000-01) was a follow-up study of Young-HUNT1, 2400 students participated in both studies (77% of the invited). Young-HUNT3 (2006-08) was a new cross-sectional study as part of HUNT3. This time 8677 adolescents participated (87% response rate). Data collection included self-reported questionnaires, structured interviews, clinical measurements and, in Young-HUNT3, buccal smears. All institutions with research expertise can apply for access to analyze HUNT data. Projects must have recommendations from The Regional Committee for Medical Research in Norway (REK) and be registered with The Norwegian Social Science Data Services (NSD).

Proper citation: Hunt Biobank (RRID:SCR_010626) Copy   

•   Source: SciCrunch Registry

http://mayoresearch.mayo.edu/mitochondrial-disease-biobank/

A biobank of blood and tissue samples from patients with known and suspected mitochondrial diseases along with data from their families. Samples are used in research to understand the family of mitochondrial disorders such as Alpers' syndrome, encephalopathy, and Friedrieich's ataxia, among many others. The goal of the biobank is to advance the understanding of mitochondrial disease and improve patient care.

Proper citation: Mayo Mitochondrial Disease Biobank (RRID:SCR_010598) Copy   

•   Source: SciCrunch Registry

http://www.lifesharing.org/index.php?option=com_content&view=article&id=5:tissue-bank&catid=4:tissue-bank&Itemid=6

Lifesharing Tissue Services provides the opportunity to improve and extend lives through the procurement, processing, storage and distribution of human tissue for transplantation and research. Originally established in 1984 to support the Burn Center at UCSD Medical Center, Lifesharing Tissue Services is a non-profit organization serving San Diego and Imperial counties in Southern California. The majority of tissues recovered by Lifesharing Tissue Services stay in this region to enable physicians to provide the best possible care for critically ill patients. Tissue grafting not only reduces pain and speeds recovery, but it also improves a patient''s quality of life. Fully accredited by the American Association of Tissue Banks (AATB) and the Food and Drug Administration (FDA), Lifesharing Tissue Services works to ensure the highest quality of tissue and technical service. Lifesharing is a member of the United Network for Organ Sharing (UNOS).

Proper citation: Lifesharing Tissue Services (RRID:SCR_004325) Copy   

•   Source: SciCrunch Registry

http://toc.lbg.ac.at/en/research-program/project-tumor-bank

As a basis for the experimental cluster projects, and for further future projects a collection of various biological specimens of cancer patients shall be established. All participating Ludwig Boltzmann Institutes (LBIs) are supplying biological specimens from tumor patients and clinical documentation. At the LBI for Gynecology and Gynecologic Oncology a tumor bank for biological specimens from gynecologic cancer patients already exists. All the procedures for sample processing and storage are well established. Existing equipment for storing tissue specimens at -196 degrees C can be used. Materials from the following malignant diseases are collected: Breast cancer Colorectal cancer Neuroendocrine tumors (NET) (Small cell lung cancer (SCLC) and Carcinoid tumors) Types of biological materials: Tissue (fresh frozen) Bone marrow Blood (serum/plasma/cell fractions) Pleural effusions Ascitic fluids Sputum Bronchial lavage Stool The biological specimens are initially processed at the respective LBIs or at their connected lab facilities. Enrichment of blood samples for disseminated tumor cells is done at the LBI for Gynecology and Gynecologic oncology. Long time storage of all materials is done at appropriate temperatures at the same institution. This LBI also coordinates the logistics. All relevant sample-specific and clinical data are surveyed at the respective LBIs and stored centralized in an on-line data bank in anonymized form, respecting all relevant regulations on data protection and security.

Proper citation: Ludwig Boltzman Tumour Bank (RRID:SCR_004322) Copy   

•   Source: SciCrunch Registry

http://www.promptprostate.com/

The MRC and Cancer Funders'' Forum (now National Cancer Research Institute, NCRI) established two cancer collaboratives in 2002, ProMPT and the Southern Collaborative. Their purpose was to increase the critical mass of basic and translational cancer researchers working on prostate cancer. The Collaboratives have both been successful in raising external grant income over the past 5 or 6 years and the current funding is very much geared around infrastructure to help with bio-marker development. This includes the establishment of biorepositories and tissue collections together with appropriate epidemiological and clinical information. The ProMPT collaborative is organized by Professor David Neal, Chair of Surgical Oncology in Cambridge. The other institutions include the Universities of Bristol, Manchester, Newcastle upon Tyne, Sheffield and York. The collaborative is very much working on translational aspects of prostate cancer research and has available to it a wide range of models. The Bristol group is working on epidemiological aspects and IGF, the Manchester group is working on stem cells, the Newcastle group is focused on target identification and validation and new drug development. Sheffield is working on model systems, bone metastasis and angiogenesis, York''s expertise is stem cells, structural biology and prostate specific gene targeting., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: ProMPT - Prostate Cancer Mechanisms of Progression and Treatment (RRID:SCR_004160) Copy   

•   Source: SciCrunch Registry

http://www.core.org/

The Center for Organ Recovery & Education (CORE) is one of 58 federally designated agencies in the United States known as a not-for-profit organ procurement organization (OPO). CORE is dedicated to promoting donation, education and research for the purpose of saving and improving the quality of life through organ, tissue and corneal transplantation. An innovative, responsive OPO, CORE plays a pivotal role between potential donors and patients awaiting transplantation. In addition to talking with families about the opportunity to donate, CORE coordinates the surgical recovery of organs, tissue and corneas, as well as the computerized matching of donated organs and placement of corneas. In 1995, CORE created the first donor card database in Pennsylvania. In 1996, the organization added tissue recovery and eye banking services to its organ recovery component. It enhanced its line of services by opening an internal laboratory in 1997, where CORE performs the necessary tests to help determine if the organs, tissue and corneas are healthy for transplantation. Since its inception more than 30 years ago, CORE has helped to provide more than 300,000 organs, tissue and corneas for transplantation. The chances for renewed health provided through CORE would not be possible without those who have said yes to donation.

Proper citation: Center for Organ Recovery and Education - CORE (RRID:SCR_004317) Copy   

•   Source: SciCrunch Registry

https://abl.azdhs.gov

THIS RESOURCE IS NO LONGER IN SERVICE, documented May 10, 2017. A pilot effort that has developed a centralized, web-based biospecimen locator that presents biospecimens collected and stored at participating Arizona hospitals and biospecimen banks, which are available for acquisition and use by researchers. Researchers may use this site to browse, search and request biospecimens to use in qualified studies. The development of the ABL was guided by the Arizona Biospecimen Consortium (ABC), a consortium of hospitals and medical centers in the Phoenix area, and is now being piloted by this Consortium under the direction of ABRC. You may browse by type (cells, fluid, molecular, tissue) or disease. Common data elements decided by the ABC Standards Committee, based on data elements on the National Cancer Institute''s (NCI''s) Common Biorepository Model (CBM), are displayed. These describe the minimum set of data elements that the NCI determined were most important for a researcher to see about a biospecimen. The ABL currently does not display information on whether or not clinical data is available to accompany the biospecimens. However, a requester has the ability to solicit clinical data in the request. Once a request is approved, the biospecimen provider will contact the requester to discuss the request (and the requester''s questions) before finalizing the invoice and shipment. The ABL is available to the public to browse. In order to request biospecimens from the ABL, the researcher will be required to submit the requested required information. Upon submission of the information, shipment of the requested biospecimen(s) will be dependent on the scientific and institutional review approval. Account required. Registration is open to everyone.

Proper citation: Arizona Biospecimen Locator (RRID:SCR_004151) Copy   

•   Source: SciCrunch Registry

http://www.bionet.umn.edu/tpf/home.html

Procure and distribute human tissue and other biological samples in support of basic, translational, and clinical cancer research at the University of Minnesota. The TPF is a centralized resource with standardized patient consent, sample collection, processing, storage, quality control, distribution, and electronic record maintenance. Since the 1996 inception of the TPF, over 61,000 tissue samples including well-preserved samples of malignant and benign tumors, organ-matched normal tissue, and other types of diseased tissues, have been collected from surgical specimens obtained at the University of Minnesota Medical Center-Fairview (UMMC-F) University Campus. Surgical pathologists are intellectually engaged in TPF functions, providing researchers with specimen-oriented medical consultation to facilitate research productivity. Prior to surgery, TPF personnel identify and consent patients for procurement of tissue, blood, urine, saliva, and ascites fluid. Within the integrated working environment of the surgical pathology laboratory, freshly obtained tissues not needed for diagnosis are selected and provided by pathologists to TPF personnel. Tissue samples are then assigned an independent code and processed. TPF staff can also work with researchers to individualize the procurement of tissues to fit specific research needs.

Proper citation: University of Minnesota Tissue Procurement Facility (RRID:SCR_004270) Copy   

•   Source: SciCrunch Registry

http://www.ataxia.org/research/ataxia-tissue-donation.aspx

A website where users can find information on donating tissue for ataxia research.

Proper citation: NAF Ataxia Tissue Donation (RRID:SCR_003893) Copy   

•   Source: SciCrunch Registry

http://www.uab.edu/medicine/tcbf/tpsf-sidebar

The Tissue Procurement Shared Facility (TPSF) of the Comprehensive Cancer Center operates as a prospective service to collect, from UAB associated hospitals, normal, malignant, benign, and diseased fresh human tissues and fluids which are then preserved appropriate to protocol. The TPSF can provide normal, malignant, benign, or diseased remnant human tissues and/or fluids from surgical resections, autopsies, or clinical procedures for IRB-approved researchers. The preservation can include fresh storage in media or saline, snap-frozen storage in liquid nitrogen, freezing in OCT for frozen section preparation, or preservation in a fixative of choice. The TPSF can also provide procurement of control tissues including uninvolved tissues or matched tissues from patients with benign disease processes. The histology laboratory can provide paraffin blocks and/or stained or unstained slides. In addition, investigators can obtain access to rare tissues through the national Cooperative Human Tissue Network (CHTN). Although the facility operates as a prospective service specializing in the preparation of samples to protocol, limited banked frozen and paraffin-embedded samples may be available. Investigators are required to complete an application and provide a copy of their IRB approval as well as a brief description of the project for which the requested samples will be utilized. Samples are provided for research purposes only. Processing fees are to offset processing costs and should be included in all grant applications.

Proper citation: UAB Comprehensive Cancer Center Tissue Procurement Shared Facility (RRID:SCR_004222) Copy   

•   Source: SciCrunch Registry

http://www.nimhans.kar.nic.in/neuropathology/neuropath2.htm#brainbank

A National Facility to promote research in Neurobiology using human nervous tissues. The brain tissues collected with informed consent of close relatives within 4-24 hours following death are frozen for Biochemical, Immuno-histochemical and Molecular Biological studies. A large number of formalin fixed brain tissues from various Neurological, Neurosurgical and Psychiatric disorders are also available for study.

Proper citation: Bangalore Brain Bank (RRID:SCR_004227) Copy   

•   Source: SciCrunch Registry

http://www.georgiacancer.org/res-tissue.php

THIS RESOURCE IS NO LONGER IN SERVICE, documented on July 17, 2013.
The Georgia Cancer Specimen and Tissue Bank is committed to a safe and reliable supply of tissue and cell products for research purposes. Work has begun already to build the state tumor bank initiative with operating sites in several locations through the state. We are confident that our results will yield a strong program that will benefit all Georgians and contribute to significant advances in cancer research and knowledge.

Proper citation: Biorepository Alliance of Georgia for Oncology (RRID:SCR_004184) Copy   

•   Source: SciCrunch Registry

http://acsr.ucsf.edu/

A biorepository for HIV-infected human biospecimens from a wide spectrum of HIV-related or associated diseases, including cancer, and from appropriate HIV-negative controls. The ACSR has formalin-fixed paraffin embedded biospecimens, fresh frozen biospecimens, malignant cell suspensions, fine needle aspirates, and cell lines from patients with HIV-related malignancies. It also contains serum, plasma, urine, bone marrow, cervical and anal specimens, saliva, semen, and multi-site autopsy speicmens from patients with HIV-related malignancies including those who have participated in clinical trials. The ACSR has an associated databank that contains prognostic, staging, outcome and treatment data on patients from whom tissues were obtained. The ACSR database contains more than 300,000 individual biospecimens with associated clinical information. Biospecimens are entered into the ACSR database by processing type, disease category, and number of cases defined by disease category.

Proper citation: AIDS and Cancer Specimen Resource (RRID:SCR_004216) Copy   

•   Source: SciCrunch Registry

https://scicrunch.org/browse/resourcesedit/SCR_004214

THIS RESOURCE IS NO LONGER IN SERVICE, documented May 18, 2022. A tumor bank that provides a large collection of cancer specimens, from breast and other cancers, annotated with clinical information. The CBCF TB enables researchers to address unanswered questions concerning the prognosis and treatment of breast cancer and other cancers. The CBCF TB website is also directed to participants interested in donating tumor tissue or blood. Biological specimens such as blood, urine, bone marrow, and ascites (fluid that sometimes collects in the abdomen) contain genetic information, just as tumor tissue does. These samples can be used in studies that may help researchers see how people with certain genetic make-ups respond to certain treatments. It can also explain why different people have different health problems. CBCF TB, formerly ARTB, was created by a merger of components of two existing Tumor-banking initiatives, the CLS Repository in Calgary and the Tumor bank of the PolyomX Program in Edmonton.

Proper citation: Canadian Breast Cancer Foundation Tumor Bank (RRID:SCR_004214) Copy   

•   Source: SciCrunch Registry

http://www.ovcare.ca/research/gynaecologic_tissue_bank/

The OvCaRe Tissue Bank is housed within the Vancouver General Hospital Department of Pathology and the British Columbia Cancer Agency. This bank contains tumour samples from over 1100 patients. The tissue samples in the bank are collected from consenting patients within 30 minutes of surgical excision and stored in a variety of forms, including snap frozen, formalin fixed, and as live cells. As of 2007, serum, plasma, and buffy coat are also being collected for every case within the tissue bank. In addition to providing research material for OvCaRe researchers, the OvCaRe Tumour Bank is more active than any other tumour bank in sending samples to research collaborators and has already contributed to 43 national and international research projects. This and other tissue banks provide the foundation for translational research in medicine. In order for these samples to be used by current technologies such as Illumina whole transcriptome sequencing, the samples must be of extremely high quality. We have currently sent a selection of our samples to The Cancer Genome Atlas Project for analysis and were told by researchers there that our samples were among the best quality that they had encountered around the world. Serum Bank The OvCaRe serum bank is located at the British Columbia Cancer Agency. This bank contains over 10,000 serum samples that have been submitted for CA-125 testing as well as samples collected from patients who have consented to have their tumours submitted to the OvCaRe Tumour Bank. Like the tumour bank, these resources are available to collaborating researchers. Ovarian Cancer Tissue Microarrays The ovarian cancer tissue microarray facility from all available early ovarian cancer cases in the province for the period 1984-2000 (541 samples) was created by Dr. Blake Gilks and is the largest tissue microarray of early ovarian cancer samples. This population based series was generated in the Genetic Pathology Evaluation Center (GPEC), a laboratory supported by a Michael Smith Foundation for Health Research Unit Grant and is being used by over 20 different local and international collaborative studies. Two other ovarian cancer tissue microarrays are also built and are available to interested collaborators. All samples in the tissue microarray are linked to clinical outcomes at the Cheryl Brown Ovarian Cancer Outcomes Unit.

Proper citation: British Columbia Gynaecologic Tissue Bank (RRID:SCR_004171) Copy   

•   Source: SciCrunch Registry

http://www.cancer.duke.edu/modules/TissueProcurement29/index.php?id=1

THIS RESOURCE IS NO LONGER IN SERVICE, documented on July 16, 2013. Over 10,000 patient consents, 5,000 banking events, and 40,000 biospecimens have been processed to date with storage of both formalin fixed paraffin embedded (FFPE) tissue and frozen tissue located within multiple freezers spanning temperatures in the range of -80 degrees to -180 degrees C depending on protocol requirements. Considerable effort continues to be expended to assure compliance with IRB, NIH and HIPAA best practices and guidelines on banking human tissues. The biorepository in place today is the result of the combined efforts of the Duke Cancer Institute (DCI) Breast SPORE, DCI Shared Resource for Tissue and Blood Procurement, and the Duke University School of Medicine Research Foundation (DUSOM-RF). The DCI and the School of Medicine Research Foundation (SOMRF) have funded the collection of frozen and fixed tissues, both malignant and benign, under an ?????????????????excess tissue????????????????? protocol that utilizes freshly excised tissue that is available for research after the needs of the pathologic workup are met. This program procures tissues from many anatomic sites including breast. Recently Duke''s Institute of Genome Science & Policy (IGSP), under the direction of Drs. Geoff Ginsburg and Tom Burke, initiated a blood collection program that spans several departments and institutes. The Breast SPORE blood collection program served as the pilot for this much larger effort. The Breast SPORE tissue and blood collection effort utilizes much of the same infrastructure and personnel that are also supported by the DCI, SOMRF, and IGSP.

Proper citation: DCI Tissue and Blood Procurement Shared Resource (RRID:SCR_004116) Copy   

•   Source: SciCrunch Registry

https://www.ctrnet.ca/

The Canadian Tumour Repository Network (CTRNet) is a not-for-profit consortium of leading provincial tumor banks and programs that furthers Canadian health research. CTRNet provides interested researchers with a streamlined process to obtain quality human tissue and human tissue products from member tumor banks. The benefits of working with CTRNet.ca include: * The ability for researchers to search for quality controlled tissue samples from Canada''''s leading tumor banks in one central location and for biobanks to display and make their biospecimens available for research users. * Learning opportunities in tissue handling, research design and relevant technology training and innovations. * Invitation to CTRNet workshops and conferences. * A resource for current news links and discussion forums about cancer research and tumor banking. The vision of CTRNet is to create new opportunities for translational cancer research that will improve cancer outcomes in Canada and beyond. Through the creation and maintenance of an online pan-Canadian network, researchers will gain unprecedented access to a new and comprehensive source of tissue and clinical data. The network is a sustainable resource and operates according to the highest scientific and ethical standards for research to benefit all Canadians. Currently CTRNet has the following member banks: * CBCF Tumor Bank Alberta * Manitoba Tumour Bank * Ontario Tumour Bank * British Columbia Cancer Agency Tumour Tissue Repository (BCCA-TTR) * Le r��seau de recherche en cancer du FRSQ * NCIC Clinical Trials Group

Proper citation: Canadian Tumour Repository Network (RRID:SCR_004192) Copy   

•   Source: SciCrunch Registry

http://www.progeriaresearch.org/cell_tissue_bank.html

The PRF Cell & Tissue Bank provides medical researchers with genetic and biological material from Progeria patients and their families, so that research on Progeria and other age-related diseases can be performed. We''ve been hard at work with the families and their physicians to gather these precious biological materials. As you know, Hutchinson-Gilford Progeria Syndrome is an extremely rare condition. Thus while access to cell lines is essential for studying the biology and genetics of the disorder, there are very few cell lines in existence. Because an integral part of PRF''s mission is to stimulate interest in, and NIH funding opportunities for, Progeria research, there is an increased need for cell lines. The PRF Cell Bank will ensure that need is met! The goals of The PRF Cell & Tissue Bank are to promote: * Sufficient availability of cells for approved research projects * Incentive for new research projects * Study of the biochemical basis for Hutchinson-Gilford Progeria Syndrome * Discoveries leading to new treatments for children with Progeria * Discovery of a cure for Progeria

Proper citation: Progeria Cell and Tissue Bank (RRID:SCR_004194) Copy   

•   Source: SciCrunch Registry